Mitophagy Inhibitors
Mitophagy is the selective degradation of damaged or redundant mitochondria through the autophagy-lysosome pathway, serving as a critical quality control mechanism for maintaining cellular energetics and redox homeostasis. The most well-characterized pathway involves the PTEN-induced kinase 1 (PINK1) and the E3 ubiquitin ligase Parkin. When mitochondrial membrane potential collapses, PINK1 stabilizes on the outer mitochondrial membrane and recruits Parkin, which ubiquitinates various surface proteins, signaling for autophagosomal engulfment. Mitophagy inhibitors are of significant interest in oncology, as many cancer cells upregulate this process to survive metabolic stress, hypoxia, and chemotherapy-induced damage. By inhibiting mitophagy, researchers aim to sensitize tumors to existing treatments and promote the accumulation of dysfunctional mitochondria, leading to apoptosis.
Several classes of mitophagy inhibitors have been identified, including small molecules that target the mitochondrial protease USP30, which normally removes ubiquitin tags to prevent mitophagy. USP30 inhibitors are currently in preclinical and early clinical development for both cancer and neurodegenerative applications. Other inhibitors, such as Mdivi-1, were initially thought to target the fission protein DRP1 but have been shown to influence mitochondrial metabolism and mitophagy more broadly. Liensinine and hydroxychloroquine are also used in research to block the late stages of the autophagic process, including mitophagosome-lysosome fusion. The research status of these inhibitors is primarily preclinical, with significant efforts focused on improving potency and selectivity.
One of the major challenges in this field is the dual role of mitophagy; while its inhibition can kill cancer cells, it may exacerbate neurodegenerative conditions like Parkinson’s disease, where mitophagy is often already impaired. Therefore, the therapeutic window and tissue-specific delivery are paramount. Furthermore, the lack of highly specific biomarkers to monitor mitophagy flux in vivo complicates clinical translation. Current strategies involve combining mitophagy inhibitors with DNA-damaging agents or kinase inhibitors to overcome drug resistance. For example, in certain leukemias and solid tumors, blocking mitophagy prevents the clearance of mitochondria damaged by BH3 mimetics, thereby enhancing the pro-apoptotic signal.
As the structural biology of proteins like PINK1 and USP30 becomes clearer, the design of next-generation, highly selective inhibitors is expected to accelerate. These tools will not only provide deeper insights into mitochondrial physiology but also offer new avenues for treating diseases characterized by "mitochondrial addiction."
